UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Neuropharmacology, 2006-05, Vol.50 (6), p.755-760

2006

Volltextzugriff (PDF)

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

Synapse (New York, N.Y.), 2012-06, Vol.66 (6), p.522-532

2012

Volltextzugriff (PDF)

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

The Journal of pharmacology and experimental therapeutics, 2002-06, Vol.301 (3), p.1020-1024

2002

Volltextzugriff (PDF)

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

British journal of pharmacology, 2003-02, Vol.138 (4), p.544-553

2003

Volltextzugriff (PDF)

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Neuropsychopharmacology (New York, N.Y.), 1996-02, Vol.14 (2), p.87-96

1996

Volltextzugriff (PDF)

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Synapse (New York, N.Y.), 2012-05, Vol.66 (5), p.435-444

2012

Volltextzugriff (PDF)

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Neuropsychopharmacology (New York, N.Y.), 2002-11, Vol.27 (5), p.699-711

2002

Volltextzugriff (PDF)

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat

Neuropharmacology, 2004-02, Vol.46 (2), p.232-242

2004

Volltextzugriff (PDF)

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Neuropsychopharmacology (New York, N.Y.), 2001-12, Vol.25 (6), p.871-880

2001

Volltextzugriff (PDF)

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Psychopharmacologia, 2002-04, Vol.160 (4), p.353-361

2002

Volltextzugriff (PDF)

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats

European journal of pharmacology, 2015-10, Vol.764, p.30-37

2015

Volltextzugriff (PDF)

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

Neuropsychopharmacology (New York, N.Y.), 2000-09, Vol.23 (3), p.250-262

2000

Volltextzugriff (PDF)

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Neuropsychopharmacology (New York, N.Y.), 2002-12, Vol.27 (6), p.949-959

2002

Volltextzugriff (PDF)

Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine

The Journal of pharmacology and experimental therapeutics, 2005-12, Vol.315 (3), p.1265

2005

Volltextzugriff (PDF)

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

Neuropharmacology, 2003-12, Vol.45 (7), p.935-944

2003

Volltextzugriff (PDF)

Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats

Neuropsychopharmacology (New York, N.Y.), 2008-11, Vol.33 (12), p.2922-2933

2008

Volltextzugriff (PDF)

LY248686, a new inhibitor of serotonin and norepinephrine uptake

Neuropsychopharmacology (New York, N.Y.), 1993, Vol.8 (1), p.23-33

1993

Volltextzugriff (PDF)

The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

Biological psychiatry (1969), 2001-04, Vol.49 (8), p.716-725

2001

Volltextzugriff (PDF)

Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats

The Journal of pharmacology and experimental therapeutics, 1999-08, Vol.290 (2), p.901

1999

Volltextzugriff (PDF)

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5 R,6 R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane

European journal of pharmacology, 1998-09, Vol.356 (2), p.109-119

1998

Volltextzugriff (PDF)

Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain

Neuropsychopharmacology (New York, N.Y.), 1993-06, Vol.8 (4), p.337-344

1993

Volltextzugriff (PDF)

Muscarinic Agonists with Antipsychotic-like Activity: Structure−Activity Relationships of 1,2,5-Thiadiazole Analogues with Functional Dopamine Antagonist Activity

Journal of medicinal chemistry, 1998-10, Vol.41 (22), p.4378-4384

1998

Volltextzugriff (PDF)

Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats

Neuroreport, 1998-10, Vol.9 (15), p.3481-3486

1998

Volltextzugriff (PDF)

Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic

The Journal of pharmacology and experimental therapeutics, 1997-05, Vol.281 (2), p.876

1997

Volltextzugriff (PDF)

1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.02,6]heptanes as New Potent Muscarinic M1 Agonists: Structure−Activity Relationship for 3-Aryl-2-propyn-1-yloxy and 3-Aryl-2-propyn-1-ylthio Derivatives

Journal of medicinal chemistry, 1999-06, Vol.42 (11), p.1999-2006

1999

Volltextzugriff (PDF)

1 – 25 von 49

Suche als RSS-Feed

Aktive Filter

ThemaRats

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(49)

Sprache

Englisch
(49)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Animals
(49)
Life Sciences & Biomedicine
(39)
Science & Technology
(39)
Male
(37)
Pharmacology & Pharmacy
(32)
Biological And Medical Sciences
(22)
Rats, Sprague-Dawley
(21)
Medical Sciences
(20)
Neuropharmacology
(19)
Neurosciences
(19)
Neurosciences & Neurology
(19)
Pharmacology. Drug Treatments
(19)
Brain - Metabolism
(15)
Psychology. Psychoanalysis. Psychiatry
(14)
Dose-Response Relationship, Drug
(13)
Norepinephrine - Metabolism
(13)
Dopamine - Metabolism
(12)
Humans
(12)
In Vitro Techniques
(12)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats

Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats

LY248686, a new inhibitor of serotonin and norepinephrine uptake

The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex

Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats

Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5 R,6 R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane

Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain

Muscarinic Agonists with Antipsychotic-like Activity: Structure−Activity Relationships of 1,2,5-Thiadiazole Analogues with Functional Dopamine Antagonist Activity

Muscarinic agonists exhibit functional dopamine antagonism in unilaterally 6-OHDA lesioned rats

Butylthio[2.2.2] (NNC 11-1053/LY297802): an orally active muscarinic agonist analgesic

1-(1,2,5-Thiadiazol-4-yl)-4-azatricyclo[2.2.1.02,6]heptanes as New Potent Muscarinic M1 Agonists: Structure−Activity Relationship for 3-Aryl-2-propyn-1-yloxy and 3-Aryl-2-propyn-1-ylthio Derivatives

Aktive Filter

Suchergebnisse filtern